InBody Co.,Ltd

KOSDAQ 041830.KQ

InBody Co.,Ltd Operating Cash Flow for the year ending December 31, 2023: USD 29.71 M

InBody Co.,Ltd Operating Cash Flow is USD 29.71 M for the year ending December 31, 2023, a 23.64% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

InBody Co.,Ltd Operating Cash Flow for the year ending December 31, 2022 was USD 24.03 M, a -5.40% change year over year.
InBody Co.,Ltd Operating Cash Flow for the year ending December 31, 2021 was USD 25.40 M, a -2.90% change year over year.
InBody Co.,Ltd Operating Cash Flow for the year ending December 31, 2020 was USD 26.16 M, a 25.39% change year over year.
InBody Co.,Ltd Operating Cash Flow for the year ending December 31, 2019 was USD 20.87 M, a 31.83% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

KOSDAQ: 041830.KQ

InBody Co.,Ltd

CEO	Dr. Ki-Chul Cha
IPO Date	Dec. 15, 2000
Location	South Korea
Headquarters	InBody Building
Employees	266
Sector	Healthcare
Industries Biotechnology 3D Printing Drugstores & Retail Pharmacies Non-Alcoholic Beverages Personal Care Pharmaceuticals Plastics Telehealth

Description

InBody Co.,Ltd provides body composition analysis solutions worldwide. The company offers body composition analyzers, blood pressure monitors, stadiometers, and body water analyzers, as well as InBody dial and bands. Its products are used in nephrology, liver disease, diabetes, nutrition, and rehabilitation applications. The company was formerly known as Biospace Co., Ltd. InBody Co.,Ltd was founded in 1996 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years